Valproic acid - Cereno Scientific
Alternative Names: CS-1Latest Information Update: 25 Apr 2025
At a glance
- Originator Cereno Scientific
- Class Anti-ischaemics; Antiarrhythmics; Antiepileptic drugs; Antimigraines; Antineoplastics; Antithrombotics; Cardiovascular therapies; Nootropics; Pentanoic acids; Small molecules; Vascular disorder therapies
- Mechanism of Action 4-aminobutyrate transaminase inhibitors; Glutamate decarboxylase stimulants; Histone deacetylase inhibitors; Neurotransmitter modulators; Plasminogen activator inhibitor-1 inhibitors; Plasminogen activators; Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension
- Discontinued Stroke; Thrombosis; Venous thromboembolism
Most Recent Events
- 25 Apr 2025 Discontinued - Phase-I for Stroke (Prevention) in Sweden (unspecified route)
- 25 Apr 2025 Discontinued - Phase-I for Thrombosis (Prevention) in Sweden (unspecified route)
- 25 Apr 2025 Discontinued - Phase-I for Venous thromboembolism in Sweden (unspecified route)